Robert L. Coleman, MD: Ovarian cancer is not a very common disease. We see about 22,000 new cases every year, and that number has been relatively consistent for more than 10 years, now. But a statistic that gets missed is, what is the prevalence? Incidence is how many new cases happen in a year. Prevalence is how many people actually have the disease. One of the characteristics that is starting to show up in different population-based statistical reviews is that the prevalence of this disease is actually increasing. How does that happen? How can you have the same incidence, year after year, but the prevalence is increasing? The answer to that question is that patients are living longer with disease.
Everybody always asks, “What’s the unmet medical need?” I always answer that question as, “We need to cure patients.” It’s absolutely clear. There’s no doubt that a patient who is diagnosed with this disease is definitely set up for a tremendous amount of clinical, personal, and financial impacts that are devastating. And so, if I had a switch that I could flip, that would change this disease, it would be that it would never happen. So, the unmet medical need is to find effective therapy. The most important effective therapy is to find the way that we could prevent this from happening at all. That’s where we make our greatest impact.
Many people will also look at statistics and say, “This disease is really lethal.” Well, if you break it down by stage, it’s actually no more lethal or survivable than breast cancer. People are saying, “How can that be?” Well, the difference is, patients with, for instance, breast, and endometrial, and cervical cancer are frequently diagnosed with early-stage disease. The symptom that brings them in is something that they didn’t expect. It isn’t associated with normal activities of daily living. In ovarian cancer, the symptomatology is bloating, pelvic pressure, urinary frequency, poor appetite, and weight loss or weight gain. These things happen all the time, so we don’t have a symptom that says, “Come in and see us when these things happen. We’ll be able to diagnose early-stage disease.” When a patient has abdominal bloating, they’ve already got metastatic disease, in many cases. So, those patients are diagnosed with advanced-stage disease, right off the bat.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More